These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36200617)

  • 1. RANK pathway in cancer: underlying resistance and therapeutic approaches.
    Tufail M; Wu C
    J Chemother; 2023 Sep; 35(5):369-382. PubMed ID: 36200617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
    Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
    Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies.
    Wu X; Li F; Dang L; Liang C; Lu A; Zhang G
    Front Cell Dev Biol; 2020; 8():76. PubMed ID: 32117996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-RANKL antibody for treatment of patients with bone metastasis from breast cancer].
    Takahashi S
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):89-94. PubMed ID: 22241358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment.
    Park SY; Kim HJ; Kim KR; Lee SK; Lee CK; Park KK; Chung WY
    Toxicol Appl Pharmacol; 2014 Mar; 275(2):152-62. PubMed ID: 24463094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-RANKL antibody for the management of bone metastasis].
    Yoneda T
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Roadmap of RANKL/RANK Pathway in Cancer.
    Casimiro S; Vilhais G; Gomes I; Costa L
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
    Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
    Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
    Li R; Zhang K; Penedo TL; Kragel CP; Grizzle WE; Hameed O; Siegal GP; Wei S
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):42-50. PubMed ID: 26200837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Involvement of RANKL/RANK pathway in bone metastasis in breast cancer].
    Yoneda T
    Clin Calcium; 2011 Aug; 21(8):1159-66. PubMed ID: 21814020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
    Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
    Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
    Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
    Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
    Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
    Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
    Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
    Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain.
    Wang K; Hackney JR; Siegal GP; Wei S
    Clin Breast Cancer; 2020 Oct; 20(5):e569-e575. PubMed ID: 32381383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutics targeting the metastatic breast cancer bone microenvironment.
    Ihle CL; Wright-Hobart SJ; Owens P
    Pharmacol Ther; 2022 Nov; 239():108280. PubMed ID: 36116682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab for treatment of breast cancer bone metastases and beyond.
    Nangia JR; Ma JD; Nguyen CM; Mendes MA; Trivedi MV
    Expert Opin Biol Ther; 2012 Apr; 12(4):491-501. PubMed ID: 22348344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.